Skip to content

Tomas Kiselak, Director at Spyre Therapeutics, sold SYRE on Jun 23, 2026

Data as of Oct 16

▼ SELL$400M4,684,781 shares at $85.31Tomas Kiselak DirectorSYRE Spyre Therapeutics, Inc.
Watch SYRE
Traded
Jun 23, 2026
Disclosed
Jun 23, 2026
Filed
The same day

Form 4s are due within two business days.

Official filing (SEC Form 4) ↗

The price around the disclosure

Tomas Kiselak, Director at Spyre Therapeutics, sold SYRE on Jun 23, 2026TRADEDDISCLOSED
SYRESimilar stocks (XLV — its sector index fund), rebased to SYRE's price on the disclosure day
SYRE since disclosure
−17.7%
after the sale
Similar stocks (XLV) since disclosure
+16.1%
XLV — its sector index fund

Change in closing price from Jun 23, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.

Our take

None of our tested rules fired on this trade.

Other trades in the same filing

  1. ▼ SELLFairmount Healthcare Fund II L.P. DirectorSYRE Spyre Therapeutics, Inc.$400Mdisclosed Jun 23 · filed the same day
  2. ▼ SELLFairmount Funds Management LLC DirectorSYRE Spyre Therapeutics, Inc.$400Mdisclosed Jun 23 · filed the same day
  3. ▼ SELLPeter Evan Harwin DirectorSYRE Spyre Therapeutics, Inc.$400Mdisclosed Jun 23 · filed the same day

See every trade on SYRE →